查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2014348

慢性阻塞性肺病（COPD）治疗市场：依产品、给药途径、通路及最终用户划分－2026年至2032年全球市场预测

Chronic Obstructive Pulmonary Disease Therapeutics Market by Product, Route Of Administration, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，慢性阻塞性肺病(COPD) 治疗市场价值将达到 234.1 亿美元，到 2026 年将增长至 251.6 亿美元，到 2032 年将达到 391.6 亿美元，复合年增长率为 7.62%。

主要市场统计数据
基准年 2025 234.1亿美元
预计年份：2026年 251.6亿美元
预测年份 2032 391.6亿美元
复合年增长率 (%) 7.62%

对 COPD（慢性阻塞性肺病）护理的临床复杂性、治疗方法演变、医疗设备创新和相关人员优先事项进行全面的背景概述。

慢性阻塞性肺病（COPD）仍然是一个复杂的临床和商业性挑战，需要製药公司、医疗设备製造商、临床医生和政策制定者共同应对。治疗格局已从单一气管扩张剂疗法发展到针对不同疾病表型的联合治疗疗法和标靶治疗。随着临床实务中对发炎特征和急性恶化风险多样性的认识不断加深，治疗决策正从统一的方案转向更个人化的策略，以平衡症状控制、预防急性恶化和长期肺功能维持。

分析美国在 2025 年实施的关税措施将如何重塑 COPD 治疗的整体供应链、筹资策略、临床供应连续性和定价优势。

美国进口关税和贸易政策的变化可能会对整个慢性阻塞性肺病（COPD）治疗生态系统产生连锁反应，改变活性成分、特殊添加剂、医疗设备组件和成品吸入器的采购成本结构。当某些原材料的关税提高时，製造商将面临更高的接收成本，并被迫重新评估其供应链设计。因此，采购团队通常会采取措施来减轻跨境关税波动的影响，例如供应商多角化、尽可能增加在地采购采购，或与位于需求点附近的契约製造（CMO）合作。

透过整合产品分类、给药途径、通路和最终用户情况等方面的细分洞察，我们推动有针对性的商业化和临床引入。

精细的市场区隔方法能够从产品分类、给药途径、分销管道和终端用户环境等方面提供可操作的洞察，这些因素共同决定了产品的定位和商业化策略。在以产品为基础的市场区隔中，支气管扩张剂仍然是缓解症状的基础，而长效支气管扩张剂与吸入性皮质类固醇和其他药物的复方製剂则有助于更全面地管理气流阻塞和降低病情加重风险。抗生素则用于治疗感染疾病引起的病情加重，而祛痰药可以改善某些患者的痰液排放。为了最大限度地发挥治疗价值，应对这些差异需要不同的证据收集策略和患者支持模式。

区域洞察重点在于全球主要地区的独特法规结构、支付方趋势、製造能力和病患就医现状。

区域趋势持续对策略产生重大影响，涵盖监管路径、病患取得途径以及医疗设备偏好等各个面向。在美洲，报销机制以及品牌药和非专利药的竞争格局推动了检验的给药技术和数位化用药依从性支援工具的快速普及，同时，支付方的严格审查也要求突破性创新必须提供强有力的卫生经济学证据。在欧洲、中东和非洲（EMEA），监管方式的多样性和报销环境的差异性有利于灵活的打入市场策略，这些策略将本地伙伴关係与区域特定的定价和准入计划相结合。在这些地区，器械的便利性和成本效益往往是采购决策中的重要考量。

这份策略性企业趋势回顾说明了製造商和医疗设备合作伙伴如何协调开发、合作和证据生成，以在 COPD 治疗产品领域中脱颖而出。

领先的製药和医疗设备公司正在调整其产品组合和伙伴关係关係，以实现慢性阻塞性肺病（COPD）治疗领域的临床差异化和营运效率。常见的策略重点包括推进器材-药物混合平台的发展，投资真实世界数据（REW）倡议以验证常规临床实践中的治疗效果，以及与数位医疗公司合作，将药物依从性和吸入支持整合到产品价值提案中。随着企业寻求扩充性且符合品质标准的生产系统，以满足医疗设备复杂的组装和供应需求，契约製造和专业吸入器供应商的重要性日益凸显。

为行业领导者提供切实可行的优先建议，以协调产品设计、证据产生、供应链韧性、支付方参与和患者支援。

产业领导者应采取平衡策略，将临床差异化与可扩展的商业性可行性结合。首先，应优先选择能够直接解决药物依从性和吸入技术实际应用障碍的设备和製剂，强调直观的设计、清晰的使用说明以及整合的数位监测功能，从而帮助临床医生获得可操作的见解。同时，应投资于有针对性的证据生成，将传统的临床终点和患者报告结局（PRO）与卫生经济学模型相结合，以直接解决支付方对长期价值的担忧。

高度透明的调查方法，详细说明了与关键相关人员的互动、二手文献的整合、监管和专利资讯的整合以及专家检验过程。

本报告的研究采用结构化、多维度的方法，整合了来自一手和二手调查的证据。一手调查包括对临床医生、呼吸科护士、医院药剂师、支付方和行业高管的定性访谈，旨在了解处方因素、设备偏好和推广障碍等方面的实际观点。此外，报告还与监管和报销专家进行了有针对性的咨询，以揭示跨区域的核准途径和支付方的决策标准。

结论强调，整合临床差异化、医疗设备创新、证据产生和供应链敏捷性对于持续成功至关重要。

总而言之，慢性阻塞性肺病（COPD）的治疗格局呈现出临床细微差别、医疗设备进步和不断演变的医疗服务模式交汇融合的特点，所有这些都要求采取综合性的策略性应对措施。相关人员科学创新与以患者为中心的器械设计、可靠的真实世界数据和稳健的供应链相结合的利益相关者，将更有能力应对医保审查和竞争压力。从以产品为中心的模式转向以综合护理解决方案为核心的治疗价值提案，将医疗服务体系、数位化支援和医护人员教育融入其中，将有助于加速产品应用并改善治疗效果。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：慢性阻塞性肺病（COPD）治疗市场：依产品划分

  • 抗生素
  • 支气管扩张剂
  • 组合药物
  • 皮质类固醇
  • 祛痰药

第九章：慢性阻塞性肺病（COPD）治疗市场：依给药途径划分

  • 吸入
    • 干粉吸入器
    • 定量喷雾吸入器
    • 喷雾器
  • 注射药物
  • 口服

第十章：慢性阻塞性肺病（COPD）治疗市场：依分销管道划分

  • 医院药房
  • 网路药房
  • 零售药房

第十一章：慢性阻塞性肺病（COPD）治疗市场：依最终使用者划分

  • 诊所
  • 居家医疗
  • 医院

第十二章：慢性阻塞性肺病（COPD）治疗市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：慢性阻塞性肺病（COPD）治疗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章慢性阻塞性肺病（COPD）治疗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国慢性阻塞性肺病（COPD）治疗市场

第十六章：中国慢性阻塞性肺病（COPD）治疗药物市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc.
  • Almirall SA
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • Aurobindo Pharma Ltd.
  • Boehringer Ingelheim International GmbH
  • Chiesi Farmaceutici SpA
  • Cipla Limited
  • CSL Limited
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Glenmark Pharmaceuticals Ltd.
  • Lupin Ltd.
  • Mylan NV
  • Novartis AG
  • Orion Corporation
  • Sandoz International GmbH
  • Sun Pharmaceutical Industries Ltd
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd
  • Theravance Biopharma, Inc.
  • Verona Pharma plc
  • Yuhan Corporation
Product Code: MRR-4311CE1A3394

The Chronic Obstructive Pulmonary Disease Therapeutics Market was valued at USD 23.41 billion in 2025 and is projected to grow to USD 25.16 billion in 2026, with a CAGR of 7.62%, reaching USD 39.16 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 23.41 billion
Estimated Year [2026] USD 25.16 billion
Forecast Year [2032] USD 39.16 billion
CAGR (%) 7.62%

Comprehensive contextual introduction outlining clinical complexity, therapeutic evolution, device innovation, and stakeholder priorities in COPD care delivery

Chronic obstructive pulmonary disease remains a complex clinical and commercial challenge that demands coordinated responses from drug developers, device manufacturers, clinicians, and policy makers. The therapeutic landscape has matured from single-agent bronchodilation toward combination regimens and targeted interventions that address heterogeneous disease phenotypes. As clinical practice increasingly recognizes variations in inflammatory profiles and exacerbation risk, therapeutic decision making has moved beyond one-size-fits-all protocols and toward more individualized strategies that balance symptomatic control, exacerbation prevention, and long-term lung function preservation.

Given the centrality of inhalation as a route of administration and the emergence of novel biologic and small molecule candidates, stakeholders must manage competing priorities: optimizing delivery technology, improving adherence, and demonstrating value to payers and health systems. Transitional trends such as expanded homecare, telehealth-enabled monitoring, and heightened scrutiny of antimicrobial stewardship further complicate care pathways. Consequently, organizations need a clear, integrated view of clinical drivers, device innovations, regulatory dynamics, and commercial levers to translate research and development investments into measurable improvements in patient outcomes.

The COPD paradigm is entering a transformative phase characterized by converging technological, scientific, and service delivery innovations that redefine clinical practice and commercial strategy. Precision approaches to patient phenotyping, including biomarkers and eosinophil-guided therapy selection, are shifting treatment algorithms toward targeted anti-inflammatory therapy for selected patient subsets. At the same time, digital health solutions for inhaler monitoring and adherence support are accelerating, enabling real-world data capture and more meaningful measures of treatment impact beyond traditional endpoints.

In parallel, device innovation continues to influence therapeutic performance and patient acceptance; the refinement of dry powder inhaler mechanisms, reformulation of pressurized metered dose inhalers to minimize propellant impact, and improvements in nebulizer efficiency are all reshaping delivery choices. Service delivery is also evolving, with a greater emphasis on homecare models, remote monitoring, and integrated care pathways that reduce hospital readmissions and streamline chronic disease management. Taken together, these shifts are compelling manufacturers to align product development, patient support programs, and evidence generation strategies to remain competitive in a landscape that prizes both clinical differentiation and operational scalability.

Analysis of how evolving United States tariff measures in twenty twenty five could realign supply chains, procurement strategies, clinical supply continuity, and pricing levers across COPD therapeutics

Changes in import tariffs and trade policies that take effect in the United States can have ripple effects throughout the COPD therapeutics ecosystem by altering the economics of sourcing active pharmaceutical ingredients, specialized excipients, device components, and finished combination inhalers. When tariffs increase on specific inputs, manufacturers face higher landed costs that incentivize re-evaluation of supply chain design. Consequently, procurement teams often respond by diversifying suppliers, increasing local content where feasible, or engaging contract manufacturing organizations closer to demand centers to reduce exposure to cross-border tariff volatility.

Moreover, tariffs can influence formulation and device decisions when cost pressures make certain delivery platforms relatively more expensive. Clinical trial supply chains also feel pressure; sponsors may prioritize local sourcing for critical study materials to avoid delays and customs-related risk. From a payer and provider perspective, any sustained increase in cost can alter formulary dynamics and tender outcomes, particularly for hospital procurement that operates on tight budget cycles. To mitigate these impacts, companies are adopting hedging strategies, renegotiating long-term supply agreements, and accelerating investments in modular manufacturing and regional production hubs that reduce dependence on tariff-affected trade lanes.

Integrated segmentation insights across product classes, administration routes, distribution pathways, and end user contexts to inform targeted commercialization and clinical adoption

A nuanced approach to segmentation yields actionable insights across product classes, routes of administration, distribution channels, and end user settings that collectively determine product positioning and commercialization strategy. Within product-based segmentation, bronchodilators remain foundational for symptomatic relief while combination products that pair long-acting bronchodilators with inhaled corticosteroids or other agents support broader control of airflow obstruction and exacerbation risk; antibiotics are deployed strategically for infectious exacerbations and mucolytics can improve sputum clearance for select patients. These distinctions require distinct evidence generation plans and patient support models to maximize therapeutic value.

Route of administration shapes both clinical outcomes and patient adoption. Inhalation continues to dominate given its direct effect on the airways, with dry powder inhalers, metered dose inhalers, and nebulizers each presenting tradeoffs in particle deposition, ease of use, and suitability for patients with limited inspiratory flow. Injectable routes are increasingly relevant for biologics targeting inflammatory pathways, while oral agents provide convenience and may complement inhaled therapy in specific cases. Distribution channel dynamics likewise influence access and adherence: hospital pharmacy procurement often prioritizes therapeutic equivalence and bulk availability, retail pharmacies deliver convenience for chronic dispensing, and online pharmacies are rising as an alternative for maintenance therapy, patient education, and adherence interventions. Finally, end user segmentation-comprising clinics, homecare environments, and hospitals-determines where resources for training, device support, and monitoring should be concentrated, as homecare expansion increases the need for remote support tools and simplified delivery systems.

Geographic intelligence highlighting distinct regulatory frameworks, payer dynamics, manufacturing capabilities, and patient access realities across major global regions

Regional dynamics continue to exert powerful influence on strategy, from regulatory pathways to patient access and device preferences. In the Americas, reimbursement mechanisms and a competitive branded and generic landscape drive rapid uptake of validated delivery technologies and digital adherence tools, while payer scrutiny necessitates robust health economic evidence for premium innovations. In Europe, Middle East & Africa, heterogeneous regulatory approaches and variable reimbursement environments favor flexible market entry strategies that combine local partnerships with regionally tailored pricing and access plans; here, device simplicity and cost-effectiveness frequently weigh heavily in procurement decisions.

Asia-Pacific presents a mosaic of advanced manufacturing capacity, growing demand, and intense competition from regional generic manufacturers; regulatory harmonization efforts in certain jurisdictions are accelerating approval for both inhaled therapies and biologics, yet country-level reimbursement remains a gating factor. Across all regions, demographic trends, urbanization, and rising awareness of chronic respiratory disease are increasing demand for integrated care pathways and patient-centric delivery models. As a result, companies must calibrate regional strategies that balance central research priorities with localized execution plans that account for regulatory nuance, payer behavior, and distribution infrastructure.

Strategic corporate landscape review describing how manufacturers and device partners are aligning development, partnerships, and evidence generation to differentiate COPD offerings

Leading pharmaceutical and device organizations are reorienting portfolios and partnerships to capture clinical differentiation and operational efficiencies in COPD therapeutics. Strategic priorities commonly include advancing device-drug combination platforms, investing in real-world evidence initiatives to substantiate outcomes in routine care, and forging collaborations with digital health firms to embed adherence and inhaler technique support into product value propositions. Contract manufacturing and specialty inhaler suppliers are gaining prominence as companies seek scalable, quality-compliant production to meet complex device assembly and delivery requirements.

Competitive differentiation increasingly rests on integrated offerings that combine optimized formulations with ergonomically designed delivery systems and patient support services. Companies pursuing biologics are aligning clinical development to specific inflammatory phenotypes while concurrently building payer dossiers that articulate long-term reductions in exacerbations and resource utilization. Smaller innovators focus on niche advantages such as ultra-fine particle delivery, propellant-free inhaler technology, or novel mucolytic chemistries, and they often partner with larger organizations for commercialization reach. Overall, corporate success depends on aligning scientific innovation with pragmatic manufacturing strategies and payer-engaged evidence generation.

Practical and prioritized recommendations for industry leaders to align product design, evidence generation, supply chain resilience, payer engagement, and patient support

Industry leaders should pursue a balanced strategy that links clinical differentiation to scalable commercial execution. First, prioritize device and formulation choices that directly address real-world adherence and technique barriers by emphasizing intuitive design, clear instructions, and integrated digital monitoring that drives actionable clinician insight. Concurrently, invest in targeted evidence generation that pairs traditional clinical endpoints with patient-reported outcomes and health economic models to speak directly to payer concerns about long-term value.

Second, strengthen supply chain resilience through diversified sourcing, regional manufacturing partnerships, and flexible contract manufacturing agreements that reduce exposure to tariff and trade disruptions. Third, adopt a patient-centric commercialization approach that extends beyond product launch to include remote support, education programs for clinics and homecare teams, and collaborations with pharmacy partners to streamline access and persistence. Finally, pursue selective strategic alliances-whether for biologic development, device innovation, or digital therapeutics-to accelerate time to market while preserving focus on core capabilities and regulatory compliance.

Transparent research methodology detailing primary stakeholder engagement, secondary literature synthesis, regulatory and patent intelligence, and expert validation processes

The research underpinning this report synthesizes primary and secondary evidence through a structured, multi-method approach. Primary research included qualitative interviews with clinicians, respiratory nurses, hospital pharmacists, payers, and industry executives to capture frontline perspectives on prescribing drivers, device preferences, and adoption barriers. These insights were complemented by targeted consultations with regulatory and reimbursement experts to illuminate approval pathways and payer decision criteria across geographies.

Secondary research encompassed systematic review of peer-reviewed clinical literature, clinical trial registries, regulatory guidance documents, and product labels to validate therapeutic mechanisms and safety profiles. Patent landscapes and scientific conference proceedings provided forward-looking signals about pipeline maturation. Throughout the process, findings were triangulated across data sources and subjected to expert validation workshops to refine conclusions and ensure practical relevance for commercial strategy and clinical translation.

Concluding synthesis emphasizing the necessity of integrated clinical differentiation, device innovation, evidence generation, and supply chain agility for sustained success

In summary, the COPD therapeutic landscape is defined by a convergence of clinical nuance, device evolution, and changing care delivery models that together demand integrated strategic responses. Stakeholders who align scientific innovation with patient-centric device design, robust real-world evidence, and resilient supply chains will be best positioned to navigate reimbursement scrutiny and competitive pressure. Transitioning from product-centric thinking to holistic care solutions-where delivery systems, digital support, and provider education form part of the therapeutic value proposition-will accelerate adoption and improve outcomes.

Looking forward, agility will be critical. Companies that proactively adapt to regional regulatory variation, tariff-related supply challenges, and evolving payer expectations can convert these potential headwinds into opportunities for differentiation. By centering decisions on demonstrable patient benefit and operational sustainability, organizations can both advance clinical care and achieve commercial success in a market that increasingly prizes measurable value.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Chronic Obstructive Pulmonary Disease Therapeutics Market, by Product

  • 8.1. Antibiotics
  • 8.2. Bronchodilators
  • 8.3. Combination Products
  • 8.4. Corticosteroids
  • 8.5. Mucolytics

9. Chronic Obstructive Pulmonary Disease Therapeutics Market, by Route Of Administration

  • 9.1. Inhalation
    • 9.1.1. Dry Powder Inhaler
    • 9.1.2. Metered Dose Inhaler
    • 9.1.3. Nebulizer
  • 9.2. Injectable
  • 9.3. Oral

10. Chronic Obstructive Pulmonary Disease Therapeutics Market, by Distribution Channel

  • 10.1. Hospital Pharmacy
  • 10.2. Online Pharmacy
  • 10.3. Retail Pharmacy

11. Chronic Obstructive Pulmonary Disease Therapeutics Market, by End User

  • 11.1. Clinics
  • 11.2. Homecare
  • 11.3. Hospitals

12. Chronic Obstructive Pulmonary Disease Therapeutics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Chronic Obstructive Pulmonary Disease Therapeutics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Chronic Obstructive Pulmonary Disease Therapeutics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Chronic Obstructive Pulmonary Disease Therapeutics Market

16. China Chronic Obstructive Pulmonary Disease Therapeutics Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. AbbVie Inc.
  • 17.6. Almirall S.A.
  • 17.7. Amgen Inc.
  • 17.8. Astellas Pharma Inc.
  • 17.9. AstraZeneca plc
  • 17.10. Aurobindo Pharma Ltd.
  • 17.11. Boehringer Ingelheim International GmbH
  • 17.12. Chiesi Farmaceutici S.p.A
  • 17.13. Cipla Limited
  • 17.14. CSL Limited
  • 17.15. Gilead Sciences, Inc.
  • 17.16. GlaxoSmithKline plc
  • 17.17. Glenmark Pharmaceuticals Ltd.
  • 17.18. Lupin Ltd.
  • 17.19. Mylan N.V.
  • 17.20. Novartis AG
  • 17.21. Orion Corporation
  • 17.22. Sandoz International GmbH
  • 17.23. Sun Pharmaceutical Industries Ltd
  • 17.24. Takeda Pharmaceutical Company Limited
  • 17.25. Teva Pharmaceutical Industries Ltd
  • 17.26. Theravance Biopharma, Inc.
  • 17.27. Verona Pharma plc
  • 17.28. Yuhan Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY BRONCHODILATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY BRONCHODILATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY BRONCHODILATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COMBINATION PRODUCTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COMBINATION PRODUCTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COMBINATION PRODUCTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY MUCOLYTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY MUCOLYTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY MUCOLYTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRY POWDER INHALER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRY POWDER INHALER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRY POWDER INHALER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY METERED DOSE INHALER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY METERED DOSE INHALER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY METERED DOSE INHALER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY NEBULIZER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY NEBULIZER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY NEBULIZER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY HOMECARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY HOMECARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 61. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 62. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 63. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 65. NORTH AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 68. NORTH AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 69. NORTH AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. LATIN AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 73. LATIN AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 75. LATIN AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 76. LATIN AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 93. MIDDLE EAST CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 94. MIDDLE EAST CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 98. AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 100. AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. ASEAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. ASEAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 110. ASEAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 112. ASEAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. ASEAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. GCC CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GCC CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 116. GCC CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 117. GCC CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 118. GCC CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. GCC CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPEAN UNION CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPEAN UNION CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPEAN UNION CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPEAN UNION CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPEAN UNION CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. BRICS CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. BRICS CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 128. BRICS CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 129. BRICS CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 130. BRICS CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. BRICS CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. G7 CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. G7 CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 134. G7 CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 135. G7 CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 136. G7 CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 137. G7 CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. NATO CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. NATO CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 140. NATO CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 141. NATO CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 142. NATO CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 143. NATO CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 146. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 147. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 148. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 149. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 150. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. CHINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 152. CHINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 153. CHINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 154. CHINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 155. CHINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. CHINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)